Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First ...
BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform ...
Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based ...
Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted progress toward its planned ...
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...
Zacks Investment Research on MSN
Should you invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund ...
Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results